Monday, July 15, 2013 4:54 pm
News Summary: 5 more countries OK Pfizer's Xeljanz
By The Associated Press
THE MARKET: Nearly 24 million people worldwide suffer from rheumatoid arthritis, a painful, often disabling immune disorder.
THE COMPETITION: Xeljanz could win patients away from pricey, injected biologic drugs approved for multiple immune disorders, including Enbrel, Humira and Remicade. They cost roughly $2,500 a month, compared to just over $2,000 for Xeljanz. It's heavily advertised in the U.S., where it was launched in November, but has dangerous potential side effects.